A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Exclusion Criteria

• •Previous participation in the current study
• •Participation in a drug study or exposure to any investigational drug or placebo within 2 months prior to (the first) drug administration in the current study
• •Employees of PRA or the Sponsor and their relatives
• •Any significant acute or chronic medical condition that presents a potential risk to the subject and/or that may compromise the objectives of the study, including active, or history of, liver disease, or intestinal disorder including irritable bowel syndrome
• •Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect pharmacokinetics; history of cholecystectomy is not allowed
• •Previous participation in the current study
• •Participation in a drug study or exposure to any investigational drug or placebo within 2 months prior to (the first) drug administration in the current study
• •Employees of PRA or the Sponsor and their relatives
• •Any significant acute or chronic medical condition that presents a potential risk to the subject and/or that may compromise the objectives of the study, including active, or history of, liver disease, or intestinal disorder including irritable bowel syndrome
• •Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect pharmacokinetics; history of cholecystectomy is not allowed